Department of Molecular and Cellular Physiology, Stanford University School of Medicine, 279 Campus Drive, Stanford, California 94305, USA.
Nature. 2012 Feb 22;482(7386):552-6. doi: 10.1038/nature10867.
Acetylcholine, the first neurotransmitter to be identified, exerts many of its physiological actions via activation of a family of G-protein-coupled receptors (GPCRs) known as muscarinic acetylcholine receptors (mAChRs). Although the five mAChR subtypes (M1-M5) share a high degree of sequence homology, they show pronounced differences in G-protein coupling preference and the physiological responses they mediate. Unfortunately, despite decades of effort, no therapeutic agents endowed with clear mAChR subtype selectivity have been developed to exploit these differences. We describe here the structure of the G(q/11)-coupled M3 mAChR ('M3 receptor', from rat) bound to the bronchodilator drug tiotropium and identify the binding mode for this clinically important drug. This structure, together with that of the G(i/o)-coupled M2 receptor, offers possibilities for the design of mAChR subtype-selective ligands. Importantly, the M3 receptor structure allows a structural comparison between two members of a mammalian GPCR subfamily displaying different G-protein coupling selectivities. Furthermore, molecular dynamics simulations suggest that tiotropium binds transiently to an allosteric site en route to the binding pocket of both receptors. These simulations offer a structural view of an allosteric binding mode for an orthosteric GPCR ligand and provide additional opportunities for the design of ligands with different affinities or binding kinetics for different mAChR subtypes. Our findings not only offer insights into the structure and function of one of the most important GPCR families, but may also facilitate the design of improved therapeutics targeting these critical receptors.
乙酰胆碱是第一个被鉴定的神经递质,通过激活一系列被称为毒蕈碱型乙酰胆碱受体(mAChRs)的 G 蛋白偶联受体(GPCRs)发挥许多生理作用。虽然这 5 种 mAChR 亚型(M1-M5)具有高度的序列同源性,但它们在 G 蛋白偶联偏好和介导的生理反应方面表现出明显的差异。不幸的是,尽管经过几十年的努力,仍未开发出具有明确 mAChR 亚型选择性的治疗剂来利用这些差异。我们在这里描述了与支气管扩张药噻托溴铵结合的 G(q/11)偶联 M3 mAChR(“M3 受体”,来自大鼠)的结构,并确定了这种临床上重要药物的结合模式。该结构与 G(i/o)偶联的 M2 受体一起,为 mAChR 亚型选择性配体的设计提供了可能性。重要的是,M3 受体结构允许在显示不同 G 蛋白偶联选择性的哺乳动物 GPCR 亚家族的两个成员之间进行结构比较。此外,分子动力学模拟表明,噻托溴铵在通往两个受体结合口袋的过程中短暂结合到变构结合位点。这些模拟为变构 GPCR 配体的结合模式提供了结构视角,并为不同 mAChR 亚型具有不同亲和力或结合动力学的配体设计提供了额外的机会。我们的发现不仅为最重要的 GPCR 家族之一的结构和功能提供了深入了解,还可能促进针对这些关键受体的改进治疗剂的设计。